Thursday, August 21, 2014 9:19:08 PM
new initiative to generate investment into the company will allow us to recommence these trials and move towards
selling the equine product on the open market. As a result, the Company is still in development and approval stage.
We are looking to raise the estimated $2million required to obtain US Food and Drug Administration approval of the
patented process for humans and to make the product available to our targeted markets. This process has continued
and has found some success following the release into the market of converted stocks. Interest in our shares has
been encouraging with the conversion of a large portion of our long-term debt into Common Stock which has in turn
necessitated our increasing the authorized capital of the Company. Although we are still short of our targetted
investment level which would allow trials to recommence, we will be looking to take advantage of the market activity
by issuing new shares in the near future as well as developing other long-term investment possibilities.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM